@imdavelee's TRT injection protocol claims, fact-checked

What did @imdavelee actually say?

Dave Lee made a specific case for what he calls the optimal TRT injectable protocol: testosterone cypionate in MCT oil, injected into the deltoid three times a week (Monday, Wednesday, Friday) using a 29-gauge, half-inch insulin syringe. He argued MCT oil eliminates allergic reactions that carrier oils like cottonseed can cause, allows thinner needles due to lower viscosity, and that cypionate edges out enanthate because of a "fractionally longer half life." He also pushed back on subcutaneous injections, saying they "don't work for a decent chunk of people" and that daily IM injections become unsustainable over years.

This is more detailed and specific than most TRT content online, and the format matters because specificity can either build credibility or expose gaps. Here, it does both.

Does the science back this up?

Partially, yes. The MCT oil viscosity claim is well-supported, and the cottonseed oil allergy concern is real, though the 5-10% reaction rate he cites is not backed by published data. The cypionate-vs-enanthate half-life edge is legitimate but clinically marginal. The subcutaneous absorption variability claim has genuine support in the literature.

On carrier oil reactions: hypersensitivity to cottonseed oil in injectable testosterone formulations is a documented phenomenon. A 2012 case series in the Journal of Allergy and Clinical Immunology (Kleinhans et al.) confirmed IgE-mediated reactions to cottonseed oil. However, a population-level rate of 5-10% is not established in any published cohort. That figure appears to be clinical observation, not peer-reviewed data, and presenting it as a near-certain rate is an overstatement.

On half-life: testosterone cypionate has a reported half-life of approximately 8 days versus roughly 4.5-7 days for enanthate, depending on the pharmacokinetic study referenced (Behre et al., 1999, Journal of Clinical Endocrinology and Metabolism). The difference is real but small enough that in clinical practice, dosing frequency matters far more than which ester you choose.

On subcutaneous absorption: a 2017 study by Spratt et al. in the Journal of Urology found subcutaneous testosterone delivery produced lower and more variable serum testosterone levels compared to IM in some patients, supporting the claim that subQ does not work uniformly for everyone.

What did they get wrong (or right)?

The MCT oil allergy claim is directionally correct but numerically unsupported. Saying "you can't be allergic to MCT oil" is too absolute. Rare reactions to MCT have been reported, and no injectable excipient is universally tolerated. The claim deserves a qualifier, not a flat assertion.

The Monday-Wednesday-Friday protocol rationale is sound. Three-times-weekly injections of a long-ester testosterone do produce more stable serum levels than once-weekly, and the practical argument about a seven-day week not dividing evenly into every-other-day dosing is legitimate. A 2021 review in Andrology (Ramasamy et al.) supports more frequent dosing intervals to reduce peak-trough fluctuation.

Where he gets it meaningfully right is the subcutaneous skepticism. The TRT community online has a vocal subQ contingent, but absorption inconsistency is real and under-discussed. His point that thinner carrier oils perform better subcutaneously is also plausible, given oil-in-fat absorption dynamics, though direct comparative pharmacokinetic data on MCT subQ versus cottonseed subQ is sparse.

What he gets wrong is the implied universality. Framing one protocol as objectively best for everyone sidesteps the reality that patient body composition, injection site anatomy, and individual pharmacokinetics mean no single protocol dominates across all patients.

What should you actually know?

If you are on TRT or considering it, protocol decisions should be driven by your own lab values, not a podcast clip. The frequency and delivery route that produces stable mid-range testosterone with manageable hematocrit and estradiol is the right protocol for you, and that requires blood work, not a blanket recommendation.

MCT oil-based testosterone formulations are generally available through compounding pharmacies and are worth discussing with a prescribing clinician if you have had injection site reactions to standard formulations. That conversation should happen with someone reviewing your history, not based on a social media protocol.

The 29-gauge insulin syringe approach for deltoid injection is genuinely low-barrier and is used in clinical practice for subcutaneous and shallow IM administration. It is not fringe. But "half-inch into the deltoid" may be insufficient for IM delivery in patients with higher body fat at that site, which is worth flagging to your provider.

Finally, the cypionate versus enanthate debate is largely irrelevant for most patients. Both are effective long-ester testosterones with similar pharmacokinetics. Availability, cost, and your clinic's formulary are more practical decision factors than a marginal half-life difference.